Drug intelligence / Profile preview

NTC015

Development stage: Unknown
Lead developer: NTC Pharma
Modality: Small Molecules
Administration: Oral

Overview

NTC015 is an innovative oral drug developed for bowel preparation prior to colonoscopy. It is formulated as sachets to be dissolved in water and aims to address unmet needs in colonoscopy preparation by improving patient compliance, palatability, and effectiveness of bowel cleansing. The drug has been evaluated in large clinical trials and is positioned as a potential new standard for colon cleansing before diagnostic procedures such as colorectal cancer screening or monitoring of chronic inflammatory bowel diseases. Developed by NTC, it has been licensed for distribution in Mexico and Latin America through Chinoin. Mechanism of action details are not publicly disclosed; the product is described only as a small molecule oral formulation for colonoscopy preparation.

Brand names: Kleerkol
Other names: NTC015NTC-015NTC 015

Beyond the preview

Go deeper on NTC015.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NTC015.

Explore the full profile